ARCHIVES

Taxol Patents Reveal Bristol Strategy to Safeguard Market Against Competitors

This article is from The Cancer Letter archive.

Vol. 23 No. 26 | July 4, 1997

Download PDF Visit The Full Archive

Related Articles

Is Everyone in Academic Medicine Unhappy? Or is it Just MD Anderson?

December 12, 2014

Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate

March 25, 2011

FDA’s Kweder cites Society of Professional Journalists’ Code of Ethics–incorrectly, SPJ says.

March 4, 2005

Researchers Plan to Extend Phase IIa Asonep Trial

August 29, 2014

CTEP Analyses Proposals For Changes In Cooperative Groups

April 25, 1986

Concept Approval Given To $7 Million In OD Recompetitions, Renewals

May 28, 1982